Regulators Accelerate Drug Review With Generative AI
The Food and Drug Administration and the European Medicines Agency are moving toward aligned, forward-looking AI rules, with the EU AI Act slated to take effect in the first half of 2026 and the FDA beginning to deploy generative AI tools to support and accelerate regulatory review. Regulators aim to produce faster, more data-driven guidance anchored in transparency, explainability, and continuous performance monitoring, which could reduce development costs and timelines and improve patient access to therapies.
Scoring Rationale
Significant industry impact due to regulatory shifts, but based on commentary with limited empirical detail.
Practice interview problems based on real data
1,500+ SQL & Python problems across 15 industry datasets — the exact type of data you work with.
Try 250 free problems
